BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SAR448851 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SAR448851\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07688213-779@assetmemo.bio
DTSTAMP:20261121T010149Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:SAR448851: Phase 2 readout est. (NCT07688213)
DESCRIPTION:SAR448851\, phase 2\, Alzheimer's Disease.\nStudy: A Study to I
 nvestigate the Safety and Effectiveness of SAR448851 in Participants With 
 Early Alzheimer's Disease\nEstimated primary completion: 31 July 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/sar448851#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07688213
URL:https://assetmemo.bio/drug/sar448851#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
